Contemporary Issues in Lung Cancer: A Nursing PerspectiveMarilyn Haas Jones and Bartlett Publishers, 2003 - 322 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. Contemporary Issues in Lung Cancer addresses all aspects of the disease from incidence, risk factors, and the biology of lung cancer, to the latest modes of treatment. Also discussed are controversies in the detection and screening of lung cancer, and the special issues facing individuals with lung cancer. |
From inside the book
Results 1-3 of 67
Page 43
... rates . Typi- cally , the major complications that are seen with a lung resection procedure are pul- monary and ... rates after surgical resection by the stage of disease . Although 50 % of the patients had Stage IV disease , 30 % had ...
... rates . Typi- cally , the major complications that are seen with a lung resection procedure are pul- monary and ... rates after surgical resection by the stage of disease . Although 50 % of the patients had Stage IV disease , 30 % had ...
Page 54
... rates were 28 % for those receiving cis- platin with the higher paclitaxel dose , 25 % for cisplatin with the lower paclitaxel dose , and 12 % for cisplatin with etoposide . One - year survival also favored the paclitaxel - treated ...
... rates were 28 % for those receiving cis- platin with the higher paclitaxel dose , 25 % for cisplatin with the lower paclitaxel dose , and 12 % for cisplatin with etoposide . One - year survival also favored the paclitaxel - treated ...
Page 55
... rate of 48 % was seen ( Capozzoli et al . , 1998 ) . Other phase II studies evaluating this combination have shown response rates ranging from 30-37 % ( Arcenas , Anderson , and Krasnow , 1999 ; Millward , Bishop , and Lehnert , 1999 ) ...
... rate of 48 % was seen ( Capozzoli et al . , 1998 ) . Other phase II studies evaluating this combination have shown response rates ranging from 30-37 % ( Arcenas , Anderson , and Krasnow , 1999 ; Millward , Bishop , and Lehnert , 1999 ) ...
Contents
SEPARATING OUT THE DIFFERENCES BETWEEN LUNG | 3 |
BIOLOGY OF LUNG CANCER | 11 |
CHALLENGES OF CONDUCTING RESEARCH IN WOMEN WITH | 19 |
Copyright | |
20 other sections not shown
Other editions - View all
Common terms and phrases
abstr advanced non-small cell agents assessment associated behavior carboplatin cell carcinoma cell lung cancer chemotherapy chest cisplatin Clinical Oncology clinical trials combination decreased depression diagnosis disease docetaxel dose drug dyspnea etoposide evaluated factors fatigue gemcitabine healthcare impact improve increased individuals with lung intervention irinotecan Journal of Clinical lung cancer patients mediastinoscopy metastasis mg/m² multidisciplinary National Cancer Institute nicotine non-small cell lung Nursing Forum nutritional Oncol Oncology Nursing Oncology Nursing Forum paclitaxel pain palliative palliative care patients with advanced patients with lung Phase II study Phase II trial physical physician postoperative potential pulmonary radiation therapy radiotherapy radon measurements regimens resection response rates risk role SCLC Seminars in Oncology side effects sleep small cell lung smoking cessation Society of Clinical stage support groups surgery surgical symptom management Table thoracic thoracotomy tion tobacco topotecan treatment tumor vinorelbine weight loss